Dr. Reddy’s Laboratories has announced that the USFDA classified its recent inspection at the Srikakulam facility as Voluntary Action Indicated (VAI). Covering GMP and pre-approval processes, the inspection has been officially closed. The company received the Establishment Inspection Report (EIR) on March 4, 2026, reinforcing regulatory compliance and operational credibility.
Dr. Reddy’s Laboratories Ltd. confirmed that the United States Food and Drug Administration (USFDA) has completed its inspection of the company’s Srikakulam manufacturing facility. The inspection outcome was classified as Voluntary Action Indicated (VAI), a favorable regulatory status that signals no significant compliance concerns requiring mandatory corrective measures.
The inspection, which focused on Good Manufacturing Practices (GMP) and pre-approval processes, has now been officially closed. On March 4, 2026, Dr. Reddy’s received the Establishment Inspection Report (EIR), further strengthening confidence in the facility’s adherence to global quality standards.
Key Highlights
-
Inspection Scope: GMP and pre-approval inspection conducted by USFDA.
-
Outcome: Classified as Voluntary Action Indicated (VAI).
-
Closure: USFDA has officially closed the inspection process.
-
EIR Issued: Establishment Inspection Report received on March 4, 2026.
-
Impact: Reinforces compliance, credibility, and operational reliability.
This regulatory milestone underscores Dr. Reddy’s commitment to maintaining world-class manufacturing standards, ensuring trust and reliability in its pharmaceutical offerings across global markets.
Sources: Dr. Reddy’s Laboratories official announcement, USFDA regulatory classification